​
​

Maravai LifeSciences (MRVI) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChartTranscripts

Maravai LifeSciences Revenue Highlights

Latest Revenue (Y)

$288.94M

Latest Revenue (Q)

$65.20M

Main Segment (Y)

Nucleic Acid Production Segment

Main Geography (Y)

North America

Maravai LifeSciences Revenue by Period

Maravai LifeSciences Revenue by Year

DateRevenueChange
2023-12-31$288.94M-67.28%
2022-12-31$883.00M10.48%
2021-12-31$799.24M181.33%
2020-12-31$284.10M98.48%
2019-12-31$143.14M15.59%
2018-12-31$123.83M-

Maravai LifeSciences generated $288.94M in revenue during NA 2023, up -67.28% compared to the previous quarter, and up 233.33% compared to the same period a year ago.

Maravai LifeSciences Revenue by Quarter

DateRevenueChange
2024-09-30$65.20M-11.17%
2024-06-30$73.40M14.37%
2024-03-31$64.18M-13.44%
2023-12-31$74.14M10.88%
2023-09-30$66.86M-2.97%
2023-06-30$68.91M-12.79%
2023-03-31$79.03M-61.40%
2022-12-31$204.71M7.03%
2022-09-30$191.26M-21.20%
2022-06-30$242.73M-0.64%
2022-03-31$244.29M6.94%
2021-12-31$228.44M11.54%
2021-09-30$204.81M-5.95%
2021-06-30$217.78M46.94%
2021-03-31$148.21M50.69%
2020-12-31$98.35M11.94%
2020-09-30$87.86M87.31%
2020-06-30$46.91M-8.00%
2020-03-31$50.98M41.77%
2019-12-31$35.96M-

Maravai LifeSciences generated $65.20M in revenue during Q3 2024, up -11.17% compared to the previous quarter, and up 94.61% compared to the same period a year ago.

Maravai LifeSciences Revenue Breakdown

Maravai LifeSciences Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 23Dec 22Dec 21
Protein Detection Segment---
Nucleic Acid Production Segment$224.77M--
Biologics Safety Testing Segment$64.18M--
Shipping and Handling-$3.20M$3.60M

Maravai LifeSciences's latest annual revenue breakdown by segment (product or service), as of Dec 23: Nucleic Acid Production Segment (77.79%), and Biologics Safety Testing Segment (22.21%).

Quarterly Revenue by Product

Product/ServiceSep 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21
Nucleic Acid Production Segment$49.95M$46.02M$58.83M$51.23M$53.27M$61.45M$189.29M$174.88M$225.25M$223.65M$212.51M$182.90M$192.52M$123.93M
Biologics Safety Testing Segment$15.25M$18.16M$15.32M$15.64M$15.65M$17.57M$15.42M$16.38M$17.48M$20.64M$15.93M$16.63M$18.21M$17.65M
Protein Detection Segment----------$5.28M$7.05M$6.63M-

Maravai LifeSciences's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: Nucleic Acid Production Segment (76.61%), and Biologics Safety Testing Segment (23.39%).

Maravai LifeSciences Revenue Breakdown by Country

Annual Revenue by Country

CountryDec 23
EMEA$49.92M
Latin And Central America$527.00K
North America$141.06M
Asia Pacific$97.44M

Maravai LifeSciences's latest annual revenue breakdown by geography, as of Dec 23: North America (48.82%), Asia Pacific (33.72%), EMEA (17.28%), and Latin And Central America (0.18%).

Quarterly Revenue by Country

CountrySep 24Mar 24Dec 23Sep 23Mar 21
EMEA$7.46M$9.37M$42.30M$7.62M$53.72M
Asia Pacific$22.92M$21.14M$72.82M$24.62M$15.98M
Latin And Central America$125.00K$307.00K$422.00K$105.00K$220.00K
North America$34.69M$33.37M$106.54M$34.52M$78.30M

Maravai LifeSciences's latest quarterly revenue breakdown by geography, as of Sep 24: North America (53.21%), Asia Pacific (35.15%), EMEA (11.45%), and Latin And Central America (0.19%).

Maravai LifeSciences Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
INCYIncyte$3.70B$962.99M
ARGXargenx SE$1.23B$401.00M
HALOHalozyme Therapeutics$829.25M$290.08M
HRMYHarmony Biosciences$582.02M$186.04M
RAREUltragenyx Pharmaceutical$434.25M$147.03M
FOLDAmicus Therapeutics$399.36M$141.52M
APLSApellis Pharmaceuticals$366.28M$176.57M
DNLIDenali Therapeutics$330.53M-
INSMInsmed$305.21M$93.42M
MRVIMaravai LifeSciences$288.94M$65.20M
LEGNLegend Biotech$285.14M$93.99M
ASNDAscendis Pharma$266.72M$95.89M
ROIVRoivant Sciences$124.80M$55.13M
ALECAlector$97.06M$15.08M
PTGXProtagonist Therapeutics$60.00M$4.67M
ARQTArcutis Biotherapeutics$59.61M$30.86M
KRYSKrystal Biotech$50.70M$83.84M
AGIOAgios Pharmaceuticals$26.82M$8.96M
ABUSArbutus Biopharma$18.14M$1.73M
CYTKCytokinetics$7.53M$463.00K
RXDXPrometheus Biosciences$6.81M$1.10M
IMVTImmunovant--
CERECerevel Therapeutics--
AKROAkero Therapeutics--
EWTXEdgewise Therapeutics--

MRVI Revenue FAQ

What is Maravai LifeSciences’s yearly revenue?

Maravai LifeSciences's yearly revenue for 2023 was $288.94M, representing a decrease of -67.28% compared to 2022. The company's yearly revenue for 2022 was $883M, representing an increase of 10.48% compared to 2021. MRVI's yearly revenue for 2021 was $799.24M, representing an increase of 181.33% compared to 2020.

What is Maravai LifeSciences’s quarterly revenue?

Maravai LifeSciences's quarterly revenue for Q3 2024 was $65.2M, a -11.17% decrease from the previous quarter (Q2 2024), and a -2.49% decrease year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $73.4M, a 14.37% increase from the previous quarter (Q1 2024), and a 6.51% increase year-over-year (Q2 2023). MRVI's quarterly revenue for Q1 2024 was $64.18M, a -13.44% decrease from the previous quarter (Q4 2023), and a -18.79% decrease year-over-year (Q1 2023).

What is Maravai LifeSciences’s revenue growth rate?

Maravai LifeSciences's revenue growth rate for the last 3 years (2021-2023) was -63.85%, and for the last 5 years (2019-2023) was 101.86%.

What are Maravai LifeSciences’s revenue streams?

Maravai LifeSciences's revenue streams in c 23 are Nucleic Acid Production Segment, and Biologics Safety Testing Segment. Nucleic Acid Production Segment generated $224.77M in revenue, accounting 77.79% of the company's total revenue Biologics Safety Testing Segment generated $64.18M in revenue, accounting 22.21% of the company's total revenue

What is Maravai LifeSciences’s main source of revenue?

For the fiscal year ending Dec 23, the largest source of revenue of Maravai LifeSciences was Nucleic Acid Production Segment. This segment made a revenue of $224.77M, representing 77.79% of the company's total revenue.